Roche

Pascal Soriot named AstraZeneca CEO

Tuesday, August 28, 2012 03:06 PM

AstraZeneca has announced Pascal Soriot’s appointment as the company’s chief executive officer. He will assume the new role and join the AstraZeneca board as an executive director as of Oct. 1.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Roche, Areva Med collaborate on novel radio-immunotherapy for cancer

Monday, July 30, 2012 11:58 AM

Global biotech Roche and Areva Med, a subsidiary Areva specializing in the development of new therapies to fight cancer, have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.

More... »

PRA participates in landmark Alzheimer’s prevention trial

Thursday, July 26, 2012 09:52 AM

PRA, a global CRO, is participating in an Alzheimer’s disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background.

More... »

Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

More... »

Roche receives FDA approval for cytomegalovirus viral load test

Friday, July 6, 2012 03:20 PM

Switzerland-based Roche has received premarket approval from the FDA for a new test to assess a patient's viral load of cytomegalovirus (CMV).

More... »

CTO launched to make Ontario preferred location for global clinical trials

Friday, July 6, 2012 12:04 PM

Clinical Trials Ontario (CTO), a province-wide entity to make Ontario the preferred location for global clinical trials activity while maintaining the highest ethical standards, has officially launched.

More... »

Roche to streamline R&D activities, close New Jersey site

Wednesday, June 27, 2012 10:46 AM

Roche has decided to consolidate activities within its research and early development division, resulting in the closure of the company’s Nutley, N.J., site. Research and development activities will be consolidated at the existing sites in Germany and Switzerland, focusing on oncology, virology, metabolism and neuroscience.

More... »